HDFC Pharma and Healthcare Fund Direct Growth

Equity
Direct
Sector - Healthcare
HDFC Pharma and Healthcare Fund Direct Growth

About the Fund

HDFC Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 4 October, 2023. The fund is managed by . The fund could potentially beat inflation in the long-run.

Key Parameters

  1. HDFC Pharma and Healthcare Fund Direct Growth has ₹905 Cr worth of assets under management (AUM) as on Jun 2024 and is less than category average.
  2. The fund has an expense ratio 1.1.

Returns

HDFC Pharma and Healthcare Fund Direct Growth has given a CAGR return of 37.86% since inception.

Holdings

HDFC Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Lupin Ltd, Dr Reddy's Laboratories Ltd, Gland Pharma Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of HDFC Pharma and Healthcare Fund Direct Growth

To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 100.00 and for SIP is INR 100.00. HDFC Pharma and Healthcare Fund Direct Growth has no lock in period.

Fund Performance
zero opening, trading, fund transfer fee
3519 people have invested ₹ 71.4L in HDFC Pharma and Healthcare Fund Direct Growth in the last three months

INDmoney Rank

Powered by IND quant engine
IND ranking is not available for this fund.
img
Among most bought funds within the category
img
No bad points found for this fund.

Fund Overview

Expense ratio1.06%
Benchmark
S&P BSE Healthcare PR
AUM₹905 Cr
Inception Date4 October, 2023
Min Lumpsum/SIP₹100/₹100
Exit Load
1%
Lock InNo Lock-in
TurnOver
0%
Risk
Risk meter
pointer
Very High Risk

Fund Distribution
as on (30-Jun-24)

  • Equity 98.1%

  • Debt & Cash 2%

Small cap
34.8%

Mid cap
34.7%

Large cap
28.6%

Sector Allocation

Jun'24

May'24

Apr'24

Health
98.4%
Basic Materials
1.6%
All changes are between Apr'24 and Jun'24

Returns for the month of Jun

  • Gainers

  • Losers

HDFC Pharma and Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered returns of 37.86% since inception (04nd Oct 2023)
Fund Allocations

Fund Allocations

This fund has an allocation of 98.05% in Equity, 0% in Debt and 1.95% in Cash related instruments
AUM size ₹905 Cr

AUM size ₹905 Cr

This fund has AUM of ₹905 Cr which is less than its category average of ₹ 1743 Cr
Expense Ratio 1.06%

Expense Ratio 1.06%

This fund has an expense ratio of 1.06% which is less than its category average expense ratio of 1.44%

Frequently Asked Questions

The current NAV of HDFC Pharma and Healthcare Fund Direct Growth is ₹13.87 as on 22-Jul-2024.
Existing (Absolute + CAGR) as on 22-Jul-2024.
HDFC Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
3.82%
3.82%
6 Month Returns
17.09%
17.09%
1 Year Returns
0%
0%
3 Years Returns
0%
0%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.06% as on June 2024
₹905 Cr as on June 2024
Sun Pharmaceuticals Industries Ltd(12.55%), Cipla Ltd(6.4%), Lupin Ltd(5.44%), Dr Reddy's Laboratories Ltd(5.3%), Gland Pharma Ltd(4.84%) as on June 2024
The alpha ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
-
-
-
As on June 2024
The alpha for HDFC Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
-
-
-
As on June 2024
The Beta for HDFC Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
-
-
-
As on June 2024
The sharpe ratio for HDFC Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
-
-
-
As on June 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
The Exit load of HDFC Pharma and Healthcare Fund Direct Growth is 1%